IndraLab
Statements
sparser
"Targeting the USP22–SIRT1 axis therefore offers a novel precision strategy for CCA: (1) developing small-molecule USP22 inhibitors or shRNA/CRISPR-mediated gene silencing to block SIRT1 stabilization, and (2) combining SIRT1 inhibitors (e.g., EX-527, Selisistat) or epigenetic drugs to achieve synergistic anti-tumor effects in USP22high/SIRT1high patients."
sparser
"Considering that USP22 typically functions through interactions with different proteins and regulates protein stability via deubiquitination, we utilized MS to investigate the binding partners of USP22 and revealed that USP22 interacts with SIRT1 and stabilizes SIRT1 expression through its deubiquitinase activity."
sparser
"This study makes several original breakthroughs in iCCA research with significant scientific and clinical implications: (1) they are the first to demonstrate USP22’s oncogenic role in iCCA through comprehensive clinical cohort analysis, functional assays, and in vivo models, establishing it as an independent adverse prognostic factor, in contrast to its controversial functions reported in other cancers; (2) the authors discovered a novel USP22–SIRT1 epigenetic axis where USP22 stabilizes SIRT1 via deubiquitination, triggering a previously unreported TAK1/Akt-ERK signaling cascade that bridges tumor metabolism, epigenetics, and signal transduction; (3) the rescue experiments revealed a synthetic-lethal interaction between USP22 and SIRT1, suggesting synergistic therapeutic potential through combined targeting; (4) clinically, the author established a USP22/SIRT1 biomarker system that correlates with tumor invasiveness and enables prognostic stratification; and (5) by validating USP22 as a druggable target and elucidating its SIRT1-mediated deacetylation mechanism, the researchers provide crucial biological rationale and preclinical evidence to accelerate development of USP22 inhibitors or SIRT1 modulators for clinical translation ( xref )."